GLP-1 Drugs: Reawakening Eating Disorders in a Broken Medical System
Introduction: Ed Returns with a Vengeance For Jenn Nourse, a 50-year-old emotional health practitioner, a decades-old monster named ‘Ed’ – her personified eating disorder – had been quiet for years. That changed in early 2024 when she began taking semaglutide, a GLP-1 agonist sold as Ozempic or Wegovy [1]. Nourse’s story […]